Tema Cardiovascular and Metabolics ETF Rating → get a piece of the profit from this land (From True Market Insiders) (Ad) Free HRTS Stock Alerts $32.67 -0.23 (-0.70%) (As of 05/17/2024 ET) Add Compare Share Share RatingsStock AnalysisChartHeadlinesHoldingsRatingsSocial MediaStock AnalysisChartHeadlinesHoldingsRatingsSocial Media Tema Cardiovascular and Metabolics ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.HRTS Aggregate RatingModerate Buy2.75Holdings in HRTS have an aggregate rating of Moderate Buy based on 421 analyst ratings issued in the past year covering 40 companies (86.6% of the portfolio).HRTS Aggregate Price Target$48.3247.89% UpsideHigh Prediction$65.13Average Prediction$48.32Low Prediction$32.74Holdings in HRTS have an aggregate price target of $48.32 and a range of $32.74 to $65.13 covering 40 companies (86.6% of the portfolio).HRTS Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy12 Buy rating(s)Moderate Buy22 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Cardiovascular and Metabolics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 40 HRTS Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.39%VRTXVertex Pharmaceuticals$445.21+1.0%4 of 5 stars2.48$432.18 -2.9%255.34%AMGNAmgen$312.47-0.7%5 of 5 stars2.52$305.65 -2.2%21Options Volume4.96%LLYEli Lilly and Company$770.00-0.1%5 of 5 stars2.84$769.53 -0.1%19Analyst ForecastShort Interest ↓Analyst Revision4.25%DXCMDexCom$131.36-0.4%5 of 5 stars2.93$141.67 7.8%14Analyst UpgradeShort Interest ↓Positive News3.07%PODDInsulet$187.27+1.0%5 of 5 stars2.82$239.44 27.9%172.96%CRNXCrinetics Pharmaceuticals$51.40-1.0%4 of 5 stars2.92$58.42 13.7%12Analyst ForecastInsider SellingShort Interest ↓2.86%CYTKCytokinetics$59.53-0.7%4 of 5 stars2.87$81.60 37.1%15Analyst Forecast2.83%MDTMedtronic$85.92+0.3%5 of 5 stars2.40$94.91 10.5%10Upcoming EarningsNews Coverage2.80%EWEdwards Lifesciences$89.14-1.1%4 of 5 stars2.58$93.88 5.3%19Analyst Upgrade2.79%ALNYAlnylam Pharmaceuticals$149.40-1.2%5 of 5 stars2.59$216.19 44.7%17Short Interest ↑2.68%BBIOBridgeBio Pharma$30.09-3.1%5 of 5 stars2.91$48.00 59.5%11Analyst ForecastShort Interest ↑News Coverage2.62%NARIInari Medical$45.75-1.2%3 of 5 stars2.71$65.71 43.6%7Insider SellingNews Coverage2.62%BSXBoston Scientific$74.65+0.1%4 of 5 stars2.95$75.32 0.9%21Analyst ForecastShort Interest ↑2.60%ASNDAscendis Pharma A/S$121.12-1.4%1 of 5 stars2.88$176.88 46.0%8Analyst ForecastNews Coverage2.52%RCKTRocket Pharmaceuticals$22.62-3.3%5 of 5 stars2.89$52.13 130.4%92.43%MREOMereo BioPharma Group$3.20-2.1%2 of 5 stars3.00$6.50 103.1%2Analyst ForecastAnalyst RevisionNews Coverage2.33%NTLAIntellia Therapeutics$26.22+0.2%4 of 5 stars2.69$66.77 154.7%13Gap Up2.30%VKTXViking Therapeutics$67.00-3.0%4 of 5 stars3.10$112.38 67.7%10Analyst ForecastNews Coverage2.29%RAREUltragenyx Pharmaceutical$41.87-1.7%4 of 5 stars2.92$87.85 109.8%122.25%WSTWest Pharmaceutical Services$355.64+0.4%5 of 5 stars2.80$435.20 22.4%5Analyst RevisionPositive News2.11%BMYBristol-Myers Squibb$44.03-0.2%5 of 5 stars2.11$60.00 36.3%192.08%IONSIonis Pharmaceuticals$37.31-0.8%5 of 5 stars2.71$59.54 59.6%14Short Interest ↓News Coverage2.05%MASIMasimo$124.10+2.9%5 of 5 stars2.43$138.71 11.8%71.75%KROSKeros Therapeutics$52.28-3.2%3 of 5 stars3.00$86.00 64.5%71.72%MLYSMineralys Therapeutics$13.00-1.1%3 of 5 stars3.00$33.50 157.7%3Gap Up1.60%OMCLOmnicell$30.44-3.9%3 of 5 stars2.33$42.20 38.6%6News CoveragePositive News1.48%ARWRArrowhead Pharmaceuticals$24.77-0.9%4 of 5 stars2.78$51.00 105.9%9Short Interest ↑Analyst RevisionNews Coverage1.45%MIRMMirum Pharmaceuticals$24.07-2.7%5 of 5 stars3.10$49.73 106.6%101.36%MDGLMadrigal Pharmaceuticals$220.06+1.3%4 of 5 stars2.73$345.09 56.8%11Insider Selling1.36%OSCROscar Health$22.52+1.7%2 of 5 stars2.67$15.00 -33.4%61.25%SWAVShockwave Medical$330.13-0.2%4 of 5 stars2.09$309.11 -6.4%11Positive News1.19%AKROAkero Therapeutics$19.92-3.9%4 of 5 stars2.88$41.13 106.5%8Analyst ForecastShort Interest ↑Analyst Revision1.08%ARCTArcturus Therapeutics$29.78-2.4%2 of 5 stars3.00$64.86 117.8%7Short Interest ↑News Coverage0.98%TNYATenaya Therapeutics$4.66+9.6%2 of 5 stars3.00$15.00 221.9%7Analyst ForecastAnalyst RevisionNews CoverageHigh Trading Volume0.82%SLNOSoleno Therapeutics$46.16+1.1%4 of 5 stars3.14$60.33 30.7%70.71%SLNSilence Therapeutics$23.00+0.3%2 of 5 stars3.00$57.25 148.9%4Upcoming EarningsAnalyst ForecastNews CoveragePositive News0.67%GPCRStructure Therapeutics$36.15+0.8%2 of 5 stars3.00$85.71 137.1%60.43%VERVVerve Therapeutics$5.98-6.3%3 of 5 stars2.75$33.00 451.8%8Insider BuyingNews Coverage0.31%SKYESkye Bioscience$12.05-1.6%1 of 5 stars3.00$22.50 86.7%2Earnings ReportNegative News0.31%SKYESkye Bioscience$12.05-1.6%1 of 5 stars3.00$22.50 86.7%2Earnings ReportNegative News This page (NASDAQ:HRTS) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceBill Clinton Backing Biden Replacement???The Freeport SocietyForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the Markets4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Cardiovascular and Metabolics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
